TARGET KRAS WITH CONFIDENCE
KRASmut PDO SCREEN
Gain competitive advantage for your "best-in-class" inhibitor by testing efficacy on a panel of 28 patient-derived organoids across multiple indications and confidently predict patient response in the clinic.
Colorectal
cancer
Lung
cancer
Pancreatic
cancer
Proven Impact
Our KRASmut models were instrumental in developing a novel bispecific antibody currently in clinical trials for head & neck cancer patients. Discover how to save time and reduce the need for in vivo testing.
Panel features
- Largest commercially available KRASmut PDO panel including more than 25 models
- Representing pivotal KRAS mutants such as G12A, G12D, G12V, G13D and many others
- Rigorously characterized, with readily available RNA or DNA sequencing data
- Diverse models encompassing both primary and metastatic tumors
- Test off-tumor toxicities with matched normal organoids
- The most competitive pricing on the market when choosing a full panel screen
Advanced screening capabilities
- Direct measurement of cell viability with an image-based viability readout
- High-throughput 3D assay format
- Test as many compound(s) as you want
- No minimum number of models to enroll
- High-data quality with 10-point dose-response curves per compound
- Inclusive of IC50 determination and IC50 heatmap generation
FREE adagrasib resistant control
For any study of more than 4 PDOs
Accelerate your KRASi development with patient-derived models
Identify promising leads
Benchmark against standard of care
Understand the mechanism of action
Investigate resistance mechanisms
Craft optimal combination
therapy
therapy
Develop co-clinical
biomarker assays
biomarker assays
Companion
diagnostics partnering
diagnostics partnering